G1 Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$202.6M
Industry:Biotech
Founded:2012
Lead Investor(s):Cormorant Asset Management

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • G1 Therapeutics's estimated annual revenue is currently $7.9M per year.
  • G1 Therapeutics received $47.0M in venture funding in May 2016.
  • G1 Therapeutics's estimated revenue per employee is $73,879
  • G1 Therapeutics's total funding is $202.6M.

Employee Data

  • G1 Therapeutics has 107 Employees.
  • G1 Therapeutics grew their employee count by 14% last year.
  • G1 Therapeutics currently has 5 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$13.2M85N/AN/A-N/A
#2
$19.1M123-17%N/A-N/A
#3
$7.9M10714%N/A-N/A
#4
$13M849%N/A-N/A
#5
N/A30N/AN/A-N/A
#6
$1.1M7N/AN/A5/5N/A
#7
$6.8M44110%N/A-N/A
#8
$230.6M1488N/AN/A-N/A
#9
$7M4522%N/A-N/A
#10
$37.5M242N/AN/A-N/A
Missing a competitor? Contribute!?
Submit

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company's pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer. G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

keywords:Biotechnology,Healthcare,Pharmaceuticals

107

Number of Employees

$7.9M

Revenue (est)

5

Current Jobs

14%

Employee Growth %

$202.6M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

G1 Therapeutics News

09/07/2019 - G1 Therapeutics to Present at HC Wainwright Annual Global ...

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology ...

09/08/2019 - Financial Comparison: Tetralogic Pharmaceuticals ...

Tetralogic Pharmaceuticals (OTCMKTS:TLOG) and G1 Therapeutics (NASDAQ:GTHX) are both medical companies, but which is the superior ...

09/08/2019 - JPMorgan Chase & Co. Has $44.45 Million Position in G1 ...

JPMorgan Chase & Co. boosted its stake in G1 Therapeutics Inc (NASDAQ:GTHX) by 27.8% in the second quarter, according to its most recent ...

G1 Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-10-17$12.5MAMedImmune VenturesArticle
2015-02-06$33.0MBMultipleArticle
2016-05-13$47.0MCCormorant Asset ManagementArticle

G1 Therapeutics Executive Hires

DateNameTitleReference
2014-01-08Seth RudnickExecutive ChairmanArticle
2014-05-21Mark VellecaCEOArticle
2017-08-04Terry MurdockSVP Development OperationsArticle
2017-11-09Barclay PhillipsCFO & SVP, Corporate DevelopmenArticle